Impact of refractoriness to bortezomib and lenalidomide on response to treatment and time on study. Time on study for all patients enrolled. *Indicates patients who discontinued due to disease progression. CR, complete response; MR, minimal response; PD, disease progression; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.